胃食管反流病

Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308-28.

• 全文
• 摘要

Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-20.

• 摘要

World Gastroenterology Organisation. Global perspective on gastroesophageal reflux disease. October 2015 [internet publication].

• 全文

Muthusamy VR, Lightdale JR, Acosta RD, et al; ASGE Standards of Practice Committee. The role of endoscopy in the management of GERD. Gastrointest Endosc. 2015;81(6):1305-10.

• 全文
• 摘要

Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017 Mar;152(4):706-15.

• 摘要

Ness-Jensen E, Hveem K, El-Serag H, et al. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016 Feb;14(2):175-82.

• 全文
• 摘要

Zhang H, Dong D, Liu Z, et al. Revaluation of the efficacy of magnetic sphincter augmentation for treating gastroesophageal reflux disease. Surg Endosc. 2016 Sep;30(9):3684-90.

• 摘要

1.  Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308-28.

• 全文
• 摘要

2.  Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-20.

• 摘要

3.  Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383-91.

• 全文
• 摘要

4.  Armstrong D, Marshall JK, Chiba N, et al; Canadian Association of Gastroenterology GERD Consensus Group. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol. 2005 Jan;19(1):15-35.

• 摘要

5.  Leason SR, Barham HP, Oakley G, et al. Association of gastro-oesophageal reflux and chronic rhinosinusitis: systematic review and meta-analysis. Rhinology. 2017 Mar 1;55(1):3-16.

• 摘要

6.  Sidhwa F, Moore A, Alligood E, et al. Diagnosis and treatment of the extraesophageal manifestations of gastroesophageal reflux disease. Ann Surg. 2017 Jan;265(1):63-7.

• 摘要

7.  DeVault KR. Extraesophageal symptoms of GERD. Cleve Clin J Med. 2003 Nov;70 Suppl 5:S20-S32.

• 摘要

8.  World Gastroenterology Organisation. Global perspective on gastroesophageal reflux disease. October 2015 [internet publication].

• 全文

9.  El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci. 2008 Sep;53(9):2307-12.

• 全文
• 摘要

10.  Eusebi LH, Fuccio L, Bazzoli F. The role of obesity in gastroesophageal reflux disease and Barrett's esophagus. Dig Dis. 2012;30(2):154-7.

• 摘要

11.  Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005 Aug 2;143(3):199-211.

• 摘要

12.  Romero Y, Cameron AJ, Locke GR III, et al. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 1997 Nov;113(5):1449-56.

• 摘要

13.  Lagergren J, Bergstrom R, Adams HO, et al. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med. 2000 Aug 1;133(3):165-75.

• 摘要

14.  Mittal RK, Balaban DH. The esophagogastric junction. N Engl J Med. 1997 Mar 27;336(13):924-32.

• 摘要

15.  Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005 Dec;129(6):1825-31.

• 摘要

16.  Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005 May;54(5):710-7.

• 全文
• 摘要

17.  American Lung Association Asthma Clinical Research Centers, Mastronarde JG, Anthonisen NR, et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med. 2009 Apr 9;360(15):1487-99.

• 摘要

18.  Locke GR III, Talley NJ, Fett SL, et al. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med. 1999 Jun;106(6):642-9.

• 摘要

19.  Lee J, Anggiansah A, Anggiansah R, et al. Effects of age on the gastroesophageal junction, esophageal motility, and reflux disease. Clin Gastroenterol Hepatol. 2007 Dec;5(12):1392-8.

• 摘要

20.  Kotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res. 2001;18:1367-1372.

• 摘要

21.  Ruszniewski P, Soufflet C, Barthélémy P. Nonsteroidal anti-inflammatory drug use as a risk factor for gastroesophageal reflux disease: an observational study. Aliment Pharmacol Ther. 2008 Nov 1;28(9):1134-9.

• 全文
• 摘要

22.  Fujiwara Y, Kubo M, Kohata Y, et al. Cigarette smoking and its association with overlapping gastroesophageal reflux disease, functional dyspepsia, or irritable bowel syndrome. Intern Med. 2011;50(21):2443-7.

• 全文
• 摘要

23.  Terry P, Lagergren J, Wolk A, et al. Reflux-inducing dietary factors and risk of adenocarcinoma of the esophagus and gastric cardia. Nutr Cancer. 2000;38(2):186-91.

• 摘要

24.  Muthusamy VR, Lightdale JR, Acosta RD, et al; ASGE Standards of Practice Committee. The role of endoscopy in the management of GERD. Gastrointest Endosc. 2015;81(6):1305-10.

• 全文
• 摘要

25.  Jobe BA, Hunter JG, Chang EY, et al. Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison. Am J Gastroenterol. 2006 Dec;101(12):2693-703.

• 摘要

26.  Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor? Am J Gastroenterol. 2008 Oct;103(10):2446-53.

• 摘要

27.  Kahrilas PJ, Sifrim D. High-resolution manometry and impedance-pH/manometry: valuable tools in clinical and investigational esophagology. Gastroenterol. 2008 Sep;135(3):756-69.

• 摘要

28.  Ravi K, Katzka DA. Esophageal impedance monitoring: clinical pearls and pitfalls. Am J Gastroenterol. 2016 Sep;111(9):1245-56.

• 摘要

29.  Sharma P, Wani S, Rastogi A, et al. The diagnostic accuracy of esophageal capsule endoscopy: a blinded, prospective study. Am J Gastroenterol. 2008 Mar;103(3):525-32.

• 摘要

30.  Eliakim R, Sharma VK, Yassin K, et al. A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol. 2005 Aug;39(7):572-8.

• 摘要

31.  Bhardwaj A, Hollenbeak CS, Pooran N. A meta-analysis of the diagnosistic accuracy of esophageal capsule endoscopy. Am J Gastroenterol. 2009 Jun;104(6):1533-9.

• 摘要

32.  Di Fede O, Di Liberto C, Occhipinti G, et al. Oral manifestations in patients with gastro-oesophageal reflux disease: a single-center case-control study. J Oral Pathol Med. 2008 Jul;37(6):336-40.

• 摘要

33.  Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008 Oct 16;359(16):1700-7.

• 摘要

34.  Hirano I, Richter JE; Practice Parameters Committee of the American College of Gastroenterology. ACG Practice Guidelines: esophageal reflux testing. Am J Gastroenterol. 2007 Mar;102(3):668-85.

• 全文
• 摘要

35.  American College of Radiology. ACR practice parameter for the performance of esophagrams and upper gastrointestinal examinations in adults (resolution 39). 2014 [internet publication].

• 全文

36.  Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology. 2005 Nov;129(5):1756-80.

• 摘要

37.  Gonsalves N, Kahrilis PJ. Eosinophilic oesophagitis in adults. Neurogastroenterol Motil. 2009 Oct;21(10):1017-26.

• 摘要

38.  Dellon ES, Gibbs WB, Fritchie KJ, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009Dec;7(12):1305-13.

• 摘要

39.  Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013 May;108(5):679-92.

• 摘要

40.  Guo H, Ma H, Wang J. Proton pump inhibitor therapy for the treatment oflaryngopharyngeal reflux: a meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2016 Apr;50(4):295-300.

• 摘要

41.  Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of Los Angeles classification. Gut. 1999 Aug;45(2):172-80.

• 摘要

42.  Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996Jul;111(1):85-92.

• 摘要

43.  Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017 Mar;152(4):706-15.

• 摘要

44.  Ness-Jensen E, Hveem K, El-Serag H, et al. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016 Feb;14(2):175-82.

• 全文
• 摘要

45.  Ichikawa H, Sugimoto M, Sugimoto K, et al. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol. 2016 Apr;31(4):716-26.

• 摘要

46.  Haastrup P, Paulsen MS, Begtrup LM, et al. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract. 2014 Dec;31(6):625-30.

• 全文
• 摘要

47.  Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017 Mar 16;(3):CD011969.

• 全文
• 摘要

48.  Du X, Hu Z, Yan C, et al. A meta-analysis of long follow-up outcomes of laparoscopic Nissen (total) versus Toupet (270°) fundoplication for gastro-esophageal reflux disease based on randomized controlled trials in adults. BMC Gastroenterol. 2016 Aug 2;16(1):88.

• 全文
• 摘要

49.  Du X, Wu JM, Hu ZW, et al. Laparoscopic Nissen (total) versus anterior 180° fundoplication for gastro-esophageal reflux disease: a meta-analysis and systematic review. Medicine (Baltimore). 2017 Sep;96(37):e8085.

• 全文
• 摘要

50.  University of Michigan Health System. Gastroesophageal reflux disease (GERD). May 2012 [internet publication].

• 全文

51.  Maret-Ouda J, Wahlin K, El-Serag HB, et al. Association between laparoscopic antireflux surgery and recurrence of gastroesophageal reflux. JAMA. 2017 Sep 12;318(10):939-46.

• 摘要

52.  Garg SK, Gurusamy KS. Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev. 2015 Nov 5;(11):CD003243.

• 全文
• 摘要

53.  Ganz RA, Peters JH, Horgan S, et al. Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med. 2013 Feb 21;368(8):719-27.

• 全文
• 摘要

54.  Saino G, Bonavina L, Lipham JC, et al. Magnetic sphincter augmentation for gastroesophageal reflux at 5 years: final results of a pilot study show long-term acid reduction and symptom improvement. J Laparoendosc Adv Surg Tech A. 2015 Oct;25(10):787-92.

• 全文
• 摘要

55.  Zhang H, Dong D, Liu Z, et al. Revaluation of the efficacy of magnetic sphincter augmentation for treating gastroesophageal reflux disease. Surg Endosc. 2016 Sep;30(9):3684-90.

• 摘要

56.  Sheu EG, Nau P, Nath B, et al. A comparative trial of laparoscopic magnetic sphincter augmentation and Nissen fundoplication. Surg Endosc. 2015 Mar;29(3):505-9.

• 摘要

57.  Yang YX, Lewis JD, Epstein S, et al. Long-term proton-pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53.

• 摘要

58.  Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004 Oct 27;292(16):1955-60.

• 摘要

59.  Herzig SJ, Howell MD, Ngo LH, et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009 May 27;301(20):2120-8.

• 摘要

60.  Chen J, Yuan YC, Leontiadis GI, et al. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol. 2012 Feb;46(2):93-114.

• 摘要

61.  Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009 Mar 31;180(7):713-8.

• 全文
• 摘要

62.  Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009 Mar 4;301(9):937-44.

• 摘要

63.  O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009 Sep 19;374(9694):989-97.

• 摘要

64.  Ray WA, Marray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010 Mar 16;152(6):337-45.

• 摘要

65.  Bhatt DL, Cryor BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. New Engl J Med. 2010 Nov 11;363(20):1909-17.

• 摘要

66.  Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010 Dec;105(12):2533-49.

• 摘要

67.  US Food and Drug Administration. FDA drug safety communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). February 2012 [internet publication].

• 全文

68.  Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016 Apr;73(4):410-6.

• 摘要

69.  Taipale H, Tolppanen AM, Tiihonen M, et al. No association between proton pump inhibitor use and risk of Alzheimer's disease. Am J Gastroenterol. 2017 Dec;112(12):1802-8.

• 摘要

70.  Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016 Feb;176(2):238-46.

• 摘要

71.  Fuchs KH, Babic B, Breithaupt W, et al. EAES recommendations for the management of gastroesophageal reflux disease. Surg Endosc. 2014;28:1753-1773.

• 全文
• 摘要

72.  Edwards SJ, Lind T, Lundell L, et al. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials. Aliment Pharmacol Ther. 2009 Sep 15;30(6):547-56.

• 全文
• 摘要

73.  Chen D, Barber C, McLoughlin P, et al. Systematic review of endoscopic treatments for gastro-oesophageal reflux disease. Br J Surg. 2009 Feb;96(2):128-36.

• 摘要

74.  Huang X, Chen S, Zhao H, et al. Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis. Surg Endosc. 2017 Mar;31(3):1032-44.

• 摘要

75.  ASGE Technology Committee; Thosani N, Goodman A, Manfredi M, et al. Endoscopic anti-reflux devices (with videos). Gastrointest Endosc. 2017 Dec;86(6):931-48.

• 摘要

76.  Zagol B, Mikami D. Advances in transoral fundoplication for oesophageal reflux. Dig Liver Dis. 2011 May;43(5):361-4.

• 摘要

77.  Bell RC, Mavrelis PG, Barnes WE, et al. A prospective registry of patients with chronic gastroesophageal reflux disease receiving transoral incisionless fundoplication. J Am Coll Surg 2012 Dec;215(6):794-809.

• 摘要

78.  Witteman BP, Conchillo JM, Rinsma NF, et al. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2015 Apr;110(4):531-42.

• 摘要

79.  Hunter JG, Kahrilas PJ, Bell RC, et al. Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial. Gastroenterology. 2015 Feb;148(2):324-33

• 全文
• 摘要

80.  Madalosso CA, Gurski RR, Callegari-Jacques SM, et al. The impact of gastric bypass on gastroesophageal reflux disease in patients with morbid obesity: a prospective study based on the Montreal Consensus. Ann Surg. 2010 Feb;251(2):244-8.

• 摘要

81.  Shaheen NJ, Falk GW, Iyer PG, et al. ACG Clinical Guideline: diagnosis and management of Barrett's esophagus. Am J Gastroenterol. 2016;111:30-50.

• 全文
• 摘要

82.  Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med. 2009 Dec 24;361(26):2548-56.

• 摘要

83.  Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006 Apr;63(4):570-80.

• 摘要